Jul 2026· Clinical and Translational Oncology· 0 citations· 61 references
Medicine
TL;DR
These clinical practice guidelines are provided to review the usefulness of molecular platforms and establish usage guidelines to direct their incorporation into clinical practice.
Abstract
Identification of molecular alterations in cancer and advances in technology have enhanced the use of molecular alterations for the diagnosis and treatment of cancer in routine clinical practice. Multi-determination platforms are now available in most Spanish hospitals. First developed in 2021, the objective of these clinical practice guidelines is to review the usefulness of molecular platforms and establish usage guidelines to direct their incorporation into clinical practice. Here, we provide updated guidelines, which include the most recent advancements in this area.
Over the past three decades, the landscape of clinically available molecular tests has evolved due to advancements in basic science cancer research and the subsequent utilization of this knowledge to develop DNA, RNA, and protein-based molecular assays for oncology that can be employed for routine clinical use in diagn...
J. Elvin· Hematology/Oncology Clinics...· 0 citations
Endometrial cancers classified as having no specific molecular profile (NSMP) represent the most prevalent molecular subtype of the disease. In this review, we summarize the immunogenomic landscape and phenotypic features of NSMP endometrial cancer and discuss current and emerging therapeutic strategies, including endo...
Tarik Silk, U. Matulonis, Panagiotis A. Konstantinopoulos· Gynecologic Oncology· 0 citations
Evidence is accumulating to support feasibility and survival benefit in patients treated with matched therapy, and the incorporation of molecular targeted therapies and immunotherapy into the perioperative setting requires clinicians to understand the role of the MTB.
Yu Fujiwara, S. Kato, R. Kurzrock· Hematology/Oncology Clinics...· 0 citations
Current FDA-approved treatments for CCA include therapies targeting HER2, IDH1, FGFR2, and other key biomarkers, including therapies targeting HER2, IDH1, FGFR2, and other key biomarkers.
Augusto Almeida, Joao Manzi, Camila Hoff et al.· Translational Oncology· 1 citation
Pediatric precision oncology has provided a greater understanding of the wide range of molecular alterations in difficult-to-treat or rare tumors with the aims of increasing survival as well as decreasing toxicity and morbidity from current cytotoxic therapies. In this article, the authors discuss the current state of...
William G. Lee, Eugene S. Kim· Hematology/Oncology Clinics...· 0 citations
